The oligometastatic state represents a distinct entity amongst those with metastatic disease and consists of patients with metastases limited in number and location, representing an intermediate state between locally confined and widely metastatic cancers. Although similar, “oligorecurence” (limited number of metachronous metastases under conditions of a controlled primary lesion) and “oligoprogressive” state (disease progression at a limited number of sites with disease controlled at other sites of disease) are distinct entities.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mliA4X
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
This paper proposes an enhanced ant colony optimization with dynamic mutation and ad hoc initialization, ACODM-I, for improving the accuracy...
-
2016-09-24T01-16-18Z Source: International Journal of Research in Medical Sciences Biswajit Majumder, Viral Tandel, Sandip Ghosh, Sharmis...
-
Antibodies, Vol. 7, Pages 6: In-Depth Comparison of Lysine-Based Antibody-Drug Conjugates Prepared on Solid Support Versus in Solution Anti...
-
Related Articles Long-acting insulin allergy in a diabetic child. Int J Immunopathol Pharmacol. 2017 Apr 01;:394632017700431 Authors...
-
ACS Nano DOI: 10.1021/acsnano.7b02426 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h1neaG via...
-
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent...
-
JPM, Vol. 8, Pages 5: Acknowledgement to Reviewers of Journal of Personalized Medicine in 2017 Journal of Personalized Medicine doi: 10.339...
-
Accumulating data have indicated that citrus polymethoxyflavones (PMFs) have the ability to affect brain function. In the present study, we ...
-
Hypopharyngeal Cancer Pharmaceutical and Healthcare Pipeline Review, H1 2017 Medgadget (blog) Latest Pharmaceutical and Healthcare di...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου